Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab with or without platinum-based chemotherapy for high-risk metastatic NSCLC
2017-004213-24Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab, tremelimumab, carboplatin, gemcitabine and pemetrexed in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: overall survival. Started Jun 2021; status: terminated.
02
Drugs
durvalumabtremelimumabcarboplatingemcitabinepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2017-004213-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004213-24.